GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2026)

GoodRx Holdings has disclosed Capital Expenditures across 8 years of filings, most recently posting $20.5 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $20.5 million, down 5.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.3 million (up 206.97% YoY), and the FY2025 annual result was $70.5 million, up 5585.4% from the prior year.
• Capital Expenditures came in at $20.5 million for Q1 2026 at GoodRx Holdings, up from $14.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $55.4 million in Q3 2025 to a low of -$21.2 million in Q2 2025.
• The 5-year median for Capital Expenditures is $645000.0 (2022), against an average of $8.9 million.
• Peak annual rise in Capital Expenditures reached 13641.44% in 2025, while the deepest fall reached 8011.19% in 2025.
• GoodRx Holdings' Capital Expenditures stood at $150000.0 in 2022, then soared by 8208.67% to $12.5 million in 2023, then sank by 98.7% to $162000.0 in 2024, then soared by 8905.56% to $14.6 million in 2025, then surged by 40.57% to $20.5 million in 2026.
• The last three Capital Expenditures figures came in at $20.5 million (Q1 2026), $14.6 million (Q4 2025), and $55.4 million (Q3 2025), per Business Quant data.